Perillartine (DL-Perillartine)
(Synonyms: 紫苏葶,DL-Perillartine) 目录号 : GC30165
Perillartine (Perilla sugar, Peryllartine) is a sweetener. Perillartine can activation of the Tas1r2 monomeric receptors of human, rhesus monkey and squirrel monkey but not mouse in a species-dependent manner.
Cas No.:30950-27-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Perillartine (Perilla sugar, Peryllartine) is a sweetener. Perillartine can activation of the Tas1r2 monomeric receptors of human, rhesus monkey and squirrel monkey but not mouse in a species-dependent manner.
| Cas No. | 30950-27-7 | SDF | |
| 别名 | 紫苏葶,DL-Perillartine | ||
| Canonical SMILES | CC(C1CC=C(/C=N/O)CC1)=C | ||
| 分子式 | C10H15NO | 分子量 | 165.23 |
| 溶解度 | DMSO : ≥ 100 mg/mL (605.22 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 6.0522 mL | 30.2608 mL | 60.5217 mL |
| 5 mM | 1.2104 mL | 6.0522 mL | 12.1043 mL |
| 10 mM | 0.6052 mL | 3.0261 mL | 6.0522 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Perillartine
Acta Crystallogr Sect E Struct Rep Online 2009 Aug 15;65(Pt 9):o2149.21577558 PMC2969981
THE CHIRAL TITLE COMPOUND [SYSTEMATIC NAME: 4-(1-methyl-vinyl)cyclo-hexene-1-carbaldehyde oxime], C(10)H(15)NO, crystallizes with two mol-ecules in the asymmetric unit, one of which shows disorder of its propenyl substituent over two sets of sites in a 50:50 ratio. In both mol-ecules, the six-membered carbaldehyde oxime ring adopts an approximate envelope conformation in which the C atom bearing the propenyl substituent represents the flap position. In both mol-ecules, the plane passing through the propenyl substituent is nearly perpendicular to the mean plane of the six-membered ring [dihedral angles = 84.6 (6) and 87.4 (3)°]. In the crystal, the two independent mol-ecules are linked by a pair O-H⋯N hydrogen bonds across a pseudo-inversion centre, generating a dimer. The unit cell of the known racemate of the title compound is similar to the cell found here, but with space group P.
Dietary supplementation with Perillartine ameliorates lipid metabolism disorder induced by a high-fat diet in broiler chickens
Biochem Biophys Res Commun 2022 Oct 15;625:66-74.35952609 10.1016/j.bbrc.2022.07.116
Lipid metabolism disorders affect the growth and jeopardize the health of poultry, thus, decreasing economic benefits. Perillartine, a sweetener derived from Perilla frutescens, has excellent potential in regulating lipid metabolism. In this study, we explored the effects of Perillartine on lipid metabolism in broiler chickens by establishing a nonalcoholic fatty liver model induced by a high-fat diet. By using network pharmacology and molecular docking, we analyzed the potential molecular targets and pathways through which Perillartine regulates lipid metabolism and alleviates fatty liver. Perillartine was found to regulate the expression of genes associated with lipogenesis, lipolysis, and lipid transport, including FASN, PPARα, CPT-1, ACCα, APOB, and APOA1 in the liver, and to decrease lipid accumulation in the liver and blood in broilers without affecting growth performance. In addition, we discovered 24 candidate targets of Perillartine, including SRD5A2 and XDH, through network pharmacology analysis and successfully constructed a compound-target-pathway-disease network. Our results suggested that Perillartine may be a promising, long-lasting therapeutic molecule for modulating lipid metabolism disorders in broilers.
Rotational Spectrum and Conformational Analysis of Perillartine: Insights into the Structure-Sweetness Relationship
Molecules 2022 Mar 16;27(6):1924.35335289 PMC8954681
We used high-resolution rotational spectroscopy coupled to a laser ablation source to study the conformational panorama of Perillartine, a solid synthetic sweetener. Four conformers were identified under the isolation conditions of the supersonic expansion, showing that all of them present an E configuration of the C=N group with respect to the double bond of the ring. The observed structures were verified against Shallenberger-Acree-Kier's sweetness theory to shed light on the structure-sweetness relationship for this particular oxime, highlighting a deluge of possibilities to bind the receptor.
Perillartine protects against metabolic associated fatty liver in high-fat diet-induced obese mice
Food Funct 2023 Jan 23;14(2):961-977.36541423 10.1039/d2fo02227c
Metabolic associated fatty liver disease is the main cause of chronic liver disease in the world, but there is still no effective treatment. In the search for drugs to treat liver steatosis, we screened 303 natural products using HepG2 cells and discovered that Perillartine derived from Perilla frutescens (L.) improved fat deposition as well as glucose homeostasis in hepatocytes. In vitro, Perillartine reduced the expression of genes involved in lipid synthesis, lipid transport, and gluconeogenesis in hepatocytes, increased the number of mitochondria, and upregulated the phosphorylation of Akt. In vivo, Perillartine reduced body weight gain and the fat rate, improved glucose metabolism and energy balance, and altered the gut microbial composition in mice given a high-fat diet. In addition, RORγ was identified as a possible target of Perillartine through pharmacophore screening. Functional studies revealed that the overexpression of RORγ blocked the effects of Perillartine, suggesting that it reduced lipid accumulation and regulated glucose metabolism by inhibiting the transcriptional activity of RORγ. Our results provide new information on a natural product inhibitor for RORγ and reveal that Perillartine is a new candidate for the treatment of obesity and metabolic associated fatty liver disease.